AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$RLMD

Shenouda Maged purchased $844K of RLMD

Shenouda Maged (Chief Financial Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.22 ($4.20–$4.25, $0.84M total) across 2 trades over 2026-09-09 to 2026-09-10.

Original reporting
SEC EDGAR · Shenouda Maged
Published Sep 11, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RLMD
Neutral
medium confidence
Mentioned
$RLMD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLMDNeutralLow
01

Why it matters

The CFO's purchase adds to his ownership, indicating personal confidence, but the modest size limits market reaction.

02

Market read

Primary insider purchase filing; modest size suggests limited immediate trading impact.

03

What to watch

Potential upcoming clinical data releases or financing events not disclosed in this filing.

Relevance 6/10Novelty 7/10Timing: filed today

Background

Form 4 disclosures provide transparent reporting of insider transactions required by the SEC.

Company-level read

Ticker impact

$RLMDNeutralMedium confidence
Context

CFO Shenouda Maged purchased 200,000 shares for $844K, increasing his stake to 1,000,000 shares.

Expected impact

Potential slight upside pressure if market perceives confidence, but limited effect.

Evidence & confidence

The purchase is a primary Form 4 filing, providing new information, yet the dollar size is under $1M, reducing material impact.

Market effects

Sector

Minimal; biotech sector may note insider confidence but no broader shift.

Regional

U.S. market only, no regional ripple.

Global

Low; limited to RLMD investors.

Counterpoint

What could challenge this read

Insider purchase could be routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Person
    Shenouda Maged

    Chief Financial Officer of Relmada Therapeutics

  • Company
    Relmada Therapeutics, Inc.

    Biopharmaceutical company developing treatments for neuropsychiatric disorders

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RLMD insider trading history →

Related articles

AUG 14
$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

fool.com6 min
AUG 6
$RLMDMed

RELMADA THERAPEUTICS, INC. (RLMD): Results of Operations and Financial Condition

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

SEC EDGAR 8-K6 min
SEP 11
$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $14.9M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 27,629 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $540.39 ($534.09–$550.71, $14.93M total) across 17 trades on 2026-09-09. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min
SEP 11
$DELLMed

Silver Lake Partners IV, L.P. (Durban Egon) sold $28.5M of DELL (indirect holdings)

Silver Lake Partners IV, L.P. sold 52,708 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $540.39 ($534.09–$550.71, $28.48M total) across 17 trades on 2026-09-09. Filed jointly with Silver Lake Technology Associates IV, L.P. (Director), SLTA IV (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min